GSK's ICOS Agonist Disappointment Another Setback For Anticancer Ambitions
Feladilimab Phase II Combination Study With Keytruda Halted
Executive Summary
GlaxoSmithKline has discontinued treatment with its ICOS agonist feladilimab in the Phase II INDUCE-3 trial upon the recommendation of the study’s data monitoring committee, another setback for the big pharma’s plans to become a major force in the cancer therapy area.